Boston Scientific (NYSE:BSX) Stock Gets Price Target Cut from UBS Group

Boston Scientific (NYSE:BSX) had its price target cut by UBS Group from $67.00 to $57.00 in a research report sent to investors on Thursday,Benzinga reports. They currently have a buy rating on the medical equipment provider’s stock.

BSX has been the topic of a number of other reports. The Goldman Sachs Group dropped their price target on Boston Scientific from $71.00 to $57.00 and set a “buy” rating on the stock in a research note on Tuesday, July 14th. Mizuho set a $50.00 price objective on Boston Scientific in a research note on Thursday. Citigroup decreased their price objective on Boston Scientific from $48.00 to $44.00 and set a “neutral” rating for the company in a report on Thursday. Wall Street Zen downgraded Boston Scientific from a “buy” rating to a “hold” rating in a report on Sunday, August 2nd. Finally, Stifel Nicolaus lowered their target price on Boston Scientific from $60.00 to $55.00 and set a “buy” rating on the stock in a research report on Monday, October 26th. One investment analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Boston Scientific presently has an average rating of “Moderate Buy” and an average target price of $61.43.

Boston Scientific Trading Down 1.8%

NYSE:BSX opened at $41.93 on Thursday. Boston Scientific has a 12 month low of $39.57 and a 12 month high of $105.65. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $60.77 billion, a price-to-earnings ratio of 17.77, a PEG ratio of 1.03 and a beta of 0.58. The firm has a fifty day simple moving average of $44.78 and a two-hundred day simple moving average of $56.88.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, October 28th. The medical equipment provider reported $0.73 earnings per share for the quarter, meeting the consensus estimate of $0.73. The firm had revenue of $5.14 billion for the quarter, compared to analyst estimates of $5.09 billion. Boston Scientific had a net margin of 16.62% and a return on equity of 18.73%. The business’s quarterly revenue was up 1.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.75 earnings per share. Analysts expect that Boston Scientific will post 3.17 EPS for the current fiscal year.

Insider Transactions at Boston Scientific

In related news, Director David C. Habiger purchased 2,100 shares of the business’s stock in a transaction on Wednesday, August 5th. The stock was acquired at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the purchase, the director owned 17,160 shares of the company’s stock, valued at approximately $816,644.40. This trade represents a 13.94% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Michael F. Mahoney acquired 186,240 shares of the firm’s stock in a transaction on Monday, August 3rd. The shares were bought at an average cost of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the acquisition, the chief executive officer directly owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. This represents a 13.27% increase in their position. The SEC filing for this purchase provides additional information. Insiders purchased a total of 189,522 shares of company stock worth $9,157,810 in the last 90 days. 0.34% of the stock is currently owned by company insiders.

Institutional Trading of Boston Scientific

Institutional investors and hedge funds have recently modified their holdings of the stock. Avantax Planning Partners Inc. grew its holdings in Boston Scientific by 4.0% during the first quarter. Avantax Planning Partners Inc. now owns 5,242 shares of the medical equipment provider’s stock worth $329,000 after buying an additional 201 shares in the last quarter. WPG Advisers LLC raised its position in Boston Scientific by 11.9% in the 1st quarter. WPG Advisers LLC now owns 1,916 shares of the medical equipment provider’s stock valued at $120,000 after buying an additional 203 shares during the last quarter. Natural Investments LLC lifted its stake in Boston Scientific by 1.3% during the 2nd quarter. Natural Investments LLC now owns 16,067 shares of the medical equipment provider’s stock valued at $685,000 after acquiring an additional 206 shares in the last quarter. 180 Wealth Advisors LLC lifted its stake in Boston Scientific by 3.6% during the 1st quarter. 180 Wealth Advisors LLC now owns 6,468 shares of the medical equipment provider’s stock valued at $406,000 after acquiring an additional 223 shares in the last quarter. Finally, MGO One Seven LLC boosted its holdings in Boston Scientific by 1.9% during the 3rd quarter. MGO One Seven LLC now owns 14,061 shares of the medical equipment provider’s stock worth $614,000 after acquiring an additional 260 shares during the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific exceeded third-quarter earnings expectations, while management continues to support its long-term growth strategy. An eight-day cyber outage reduced quarterly sales by approximately $150 million, suggesting some of the impact may be temporary. Boston Scientific: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Some analysts still see upside: Robert W. Baird raised its price target to $51, while UBS, BTIG Research and Sanford C. Bernstein retained buy or outperform-equivalent ratings, although each lowered its target. Analysts Revise Forecasts After Q3 Results
• Neutral Sentiment: Barclays and Wells Fargo both maintain equal-weight ratings with $45 price targets, indicating limited expected upside from current levels and a wait-and-see stance.
• Negative Sentiment: Boston Scientific cut its fiscal 2026 guidance below analyst expectations, and its fourth-quarter outlook points to weaker sales. Management expects full-year organic revenue growth of about 4%, while analysts see growth challenges extending into 2027. BSX Q3 Earnings Call Flags Growth Challenges
• Negative Sentiment: The cyber incident, weakness in electrophysiology and WATCHMAN heart-device products, and pricing pressure in China are raising concerns about near-term revenue growth and execution. Boston Scientific Faces Cyber Incident and Product Pressures
• Negative Sentiment: Several firms downgraded the stock, including TD Cowen, JPMorgan, Oppenheimer and Needham. TD Cowen cut its rating to hold and reduced its target from $56 to $46, while Zacks added BSX to its Strong Sell list. New Strong Sell Stocks for October 30th
• Negative Sentiment: Relative to Intuitive Surgical, Boston Scientific is viewed as having weaker earnings momentum and less attractive near-term growth, adding competitive pressure to the investment case. Intuitive Surgical vs. Boston Scientific

About Boston Scientific

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.